Avidity plans to double the number of participants receiving 4 mg/kg of AOC 1001 in MARINA Open-Label Extension (MARINA-OLE™) study by dose escalating participants currently on 2 mg/kg of AOC 1001 FDA ...
On track to complete enrollment in del-desiran HARBORTM Phase 3 and potential registrational del-brax biomarker cohort as well as initiate global pivotal trial for del-brax by mid-2025 Eric Mosbrooker ...
Wells Fargo analyst Yanan Zhu assigned a Buy rating on Avidity Biosciences (RNA – Research Report) yesterday and set a price target of $50.00. Yanan Zhu has given his Buy rating due to a combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback